Latest Conference Articles

November 5th 2015, 12:32pm

PER® Chemotherapy Foundation Symposium (CFS)

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

November 4th 2015, 2:42pm

PER® Chemotherapy Foundation Symposium (CFS)

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

November 4th 2015, 2:12pm

PER® Chemotherapy Foundation Symposium (CFS)

Monoclonal antibodies are poised to revolutionize the treatment of adult patients with relapsed acute lymphoblastic leukemia, specifically blinatumomab and inotuzumab ozogamicin.

November 4th 2015, 1:59pm

PER® Chemotherapy Foundation Symposium (CFS)

Optimizing outcomes with novel antibodies in multiple myeloma will involve combination regimens with established agents.

November 4th 2015, 1:31pm

PER® Chemotherapy Foundation Symposium (CFS)

The landscape for the diagnosis and treatment of polycythemia vera (PV) is changing, and that's good news for patients and practitioners who can look to improvements ahead.

November 4th 2015, 12:52pm

PER® Chemotherapy Foundation Symposium (CFS)

C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.

November 4th 2015, 12:39pm

PER® Chemotherapy Foundation Symposium (CFS)

B-cell pathway inhibitors have shown impressive survival benefits for patients with chronic lymphocytic leukemia, but require careful monitoring and possible suspension to control adverse events.

November 4th 2015, 6:00am

LUGPA Annual Meeting

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

October 27th 2015, 2:12pm

International Thyroid Congress

John Copland, PhD, faculty member in the department of cancer biology, Mayo Clinic, explains his research on patient-derived xenograft (PDX) models in anaplastic thyroid cancer.

October 25th 2015, 9:00am

ASTRO Annual Meeting

The oral corticosteroid dexamethasone significantly decreased flares of bone pain when added to radiation therapy in patients with metastatic cancer.

October 25th 2015, 5:00am

ASTRO Annual Meeting

Rates of overall survival, disease-free survival, and local control were found to be comparable in select patients with early-stage breast cancer who underwent accelerated partial breast irradiation using multicatheter brachytherapy versus conventional whole breast irradiation.

October 24th 2015, 9:00am

ASTRO Annual Meeting

The additon of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial.

October 24th 2015, 5:00am

ASTRO Annual Meeting

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

October 23rd 2015, 2:28pm

International Thyroid Congress

Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.

October 23rd 2015, 1:21pm

International Thyroid Congress

Coexisting mutations in BRAF and TERT may be associated with an aggressive phenotype and higher recurrence rates for patients with locally advanced well-differentiated thyroid cancers.

October 23rd 2015, 12:56pm

International Thyroid Congress

The recent American Thyroid Association guidelines to abstain from cytological evaluation by biopsy for patients with thyroid cancer on the basis of having thyroid nodules ≤1 cm is not advisable.

October 23rd 2015, 8:22am

ASTRO Annual Meeting

Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer and brain metastases.

October 22nd 2015, 2:35pm

International Thyroid Congress

Pazopanib demonstrated significant clinical activity for patients with RAI-refractory differentiated thyroid cancer; however, a predictive biomarker for the therapy could not be uncovered.

October 22nd 2015, 2:10pm

International Thyroid Congress

Researchers have identified molecular markers in medullary thyroid cancer that were associated with response to vandetanib and the development of metastases.

October 22nd 2015, 1:12pm

International Thyroid Congress

Stephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.